CervoMed Presents Interim Data on Neflamapimod's Impact on Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
CervoMed Inc. presented 24-week interim biomarker data from the U.S. cohort of its Phase 2a clinical trial for neflamapimod, an oral p38α inhibitor, in patients with nonfluent variant primary progressive aphasia (nfvPPA). The findings, presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston, indicate that participants with higher plasma levels of neflamapimod showed a reduction in plasma neurofilament light chain (NfL). NfL is a crucial biomarker for neuronal damage that typically increases over time in nfvPPA patients. Specifically, participants in the upper third of plasma drug levels (n=6) experienced a median 4.5 pg/mL reduction in NfL over 24 weeks, while those in the lower two-thirds (n=12) showed a median increase of 4.35 pg/mL, consistent with the natural progression of untreated nfvPPA. This suggests an early biological signal of drug activity, offering hope for a condition with no approved therapies.